We're getting closer all the time
Tour de Cure has now funded a total of 40 breakthroughs.
A huge thank you to our supporters who raise the funds to make this possible and to the brilliant researchers, scientists and cancer institutions who are working tirelessly to outsmart cancer and make a better tomorrow for us all.
Stay tuned for more news of our additional four breakthroughs!
1. Dr Paul Timpson – the Garvan Institute
This article details the work of funded scientists Dr. Paul Timpson and company at the Garvan Institute of Medical Research uncovering a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it ‘softer’ and more responsive to chemotherapy.
Professor Michelle Haber & Dr Glenn Marshall
Every year, 950 Australian children and adolescents are diagnosed with cancer and on average every week around 3 die of cancer. This article details the highly successful works of the Children's Cancer Institute (CCIA), taking research and technologies into several different cancer types into viable treatments for children affected by cancer. These successes were achieved in collaboration with the Kids Cancer Centre (KCC) at Sydney Children's Hospital.
Dr. Charles Bailey – Targeted Gene Therapy Research
Normal white blood cells make use of a molecular ‘trash can’ to control many aspects of our body’s cellular defences. More than a hundred thousand white blood cells per second are produced in everyone's body and their maturation must be carefully controlled. This article unveiled how commonly occurring stretches of DNA that interrupt genes (known as introns) play a crucial role in controlling gene expression.
Dr Bryan Day – Glioblastoma
This article explores ways to target the protein EphA3 which is found in large amounts in aggressive, adult Glioblastoma (a highly invasive Brain Cancer) and negatively affects survival rates. Therapies targeting this molecule significantly slow tumour progression. The information revealed in this research will improve survival rates in the future for many adult patients facing a Glioblastoma diagnosis.
Dr Christopher J. Chan – Cellular reactions in the field of immunology
This is a review based on Dr Chan's work and others, which outlines how a particular immune cell called an NK cell is able to recognise and suppress cancer. Also, it outlines how to target these cells therapeutically for the treatment of cancer.
Dr Christopher J. Chan – Contribution of a surface protein
The work outlines the contribution of a surface protein that is expressed on immune cells to progression of Graft versus Host Disease.
Dr Christopher J. Chan – Importance of immune system
This work outlines that the immune system is important in the efficacy of a drug that is able to target genetic abnormalities in lymphoma.
Dr Christopher J. Chan – Interaction of two immune proteins
This work characterises the novel interaction of two immune proteins and their role in regulating the function of NK cells.
Dr Christopher J. Chan – Detecting cancer cells early
This work reports a novel mechanism by which the immune system can sense cellular dysfunction that can lead to cancer development at a very early stage, outlining the importance of the immune system in the early detection of cancer cells.
Dr Christopher J. Chan – Biology & function of a protein family
This is a review based on my work and others that summarises the biology and function of a protein family highly expressed in the immune system that has become very attractive for therapeutic targeting in cancer.
Dr Christopher J. Chan – Different signals can affect the function of the NK cells
This work shows how different signals can affect the function of NK cells and how these could be used therapeutically to tune these cells to have specific functions in particular disease contexts.
Dr Christopher J. Chan – Surface protein importance
This is the first work describing the function of a novel surface protein that is highly expressed in the immune system. Dr Chan and his team characterised where this protein is found and which immunological processes it is involved in.
Dr Christopher J. Chan - Regulation of NK Cell functions
This is the first work describing the function of a novel surface protein that is highly expressed in the immune system. We characterised where this protein is found and which immunological processes it is involved in.
Dr Christopher J. Chan – Cutting Edge
This work shows the importance of a surface protein in activating an immune cell known as a T cell that is very important in suppressing cancer development.
The Garvan Institute of Medical Research – Ovarian cancer research
This study focused on the protein ZNF300P1 and it's behaviour/functions within Ovarian Cancer tissue. The findings revealed that it plays an important role in regulating key cell cycles and cell motility networks in human ovarian surface epithelial cells. It also may play a role in promoting metastasis in ovarian cancer cells.
Dr Tracy Putoczki and Dr Chen Chen Jiang – Gastrointestinal cancers
In their exploration of the Cytokine IL-11, these researchers exposed a potential target for future cancer treatments that will assist in the suppression of human gastrointestinal tumours.
Dr Daniel Speidel – Cellular Stress Responses
In response to hazardous agents, cells activate a range of complicated signalling pathways. These so-called cellular stress responses are pivotal for tumour suppression and also the success of radio- and chemotherapy. The EBook features 12 articles on cellular stress responses (review papers as well as original research articles presenting new findings) written by leading scientists in the field.
Dr Daniel Speidel – Tumour Suppression
The tumour suppressor p53 is a central player in cellular DNA damage responses and one of the most extensively studied genes in cancer research. In this review, Dr Speidel summarises current knowledge on p53-controlled DNA damage responses, commenting also on recent controversially discussed findings.
Dr Daniel Speidel – Tumour Suppression
In this paper they describe a completely unexpected function of a protein that many cancers produce in abnormally high levels. Although previously described as cancer-promoting they report that depending on the exact circumstances the same protein can also enhance tumour suppression.
Dr Daniel Speidel – Mutations in SIPA1L3
This paper reports mutations in a poorly characterised gene to be responsible for congenital eye disease (blindness) and clarifies their functional consequences. This paper reports that mutations in this gene are also associated with cancer.
Murdoch Children's Research Institute – Birth weight and childhood cancer
Evidence relating childhood cancer to high birth weight is derived primarily from registry and case–control studies. We aimed to investigate this association, exploring the potential modifying roles of age at diagnosis and maternal anthropometrics, using prospectively collected data from the International Childhood Cancer Cohort Consortium.
Dr Daniel Speidel - how RUNX1 contributes to the success of radiation and chemotherapy
We report a novel function of one of the most prominent leukaemia-associated genes. Our findings show how RUNX1 contributes to the success of radiation and chemotherapy and explain why most leukaemia patients with RUNX1-mutations are resistant to chemotherapy. Thereby, our results provide the basis to overcome therapy resistance in leukaemia.
23. Dr Rosemary Sutton, Dr Toby Trahair - identifying high-risk paediatric acute lymphoblastic leukaemia relapse
Childhood acute lymphoblastic leukaemia (ALL) is a type of cancer in which the bone marrow makes too many immature lymphocytes (a type of white blood cell). Leukaemia may affect red blood cells, white blood cells and platelets. ALL is the most common cancer found in children and usually gets worse quickly if it is not treated. The researchers conclude that the incorporation of a risk score system will enable better identification of newly diagnosed ALL patients who may have therapy reduced, and of those high-risk patients in need of early intensification of therapy to prevent relapse.
24. Dr Glenn Guerra - Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma
Anal squamous carcinoma is a rare cancer with a high cure rate, making the research into the treatment of locorregional failure of surgical relapse difficult to assess. These surgical procedures are followed in the event that primary treatment (typically chemotherapy) fails. Most patients can be saved, with a positive resection margin being a strong predictor of further relapse and poor outcome.
25. Professor John Rasko, Dr Amy Marshall, Dr Chuck Bailey - Impact of Genetic Alterations on Endometrial Cancer
Research at the Gene & Stem Cell Therapy Program, Centenary Institute, Sydney has led to new insights into the effect of genetic alterations and the impact on patients suffering from endometrial (or uterine) cancer. The research found that genetic alterations in a specific gene (the tumour suppressor gene CTCF) occur in one-fifth of women with endometrial cancers. Their data proves that loss of activity of this essential genome organising protein can lead to a life-threatening production of tumours.
26. CCIA David Ziegler - Glioma
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
27. CCIA - M. Tsoli, D. Ziegler - High risk pediatric cancer
Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.
29. CCIA - J R Lynch
Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia.
30. CCIA - Rosemary Sutton, Tobias Trahir - Acute lymphoblastic leukaemia
Enrichment of atypical hyperdiploidy and IKZF1 deletions detected by SNP-mircorarray in high-risk Australian AIEOP-BFM B-cell acute.
31. CCIA - Glenn Marshall - High-risk childhood acute lymphoblastic leukemia
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneric transplantation.
32. CCIA - Rosemary Sutton - Acute lymphoblastic leukaemia
Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia
33. CCIA - Jenny Y Wang - Acute Myeloid leukemia
Targeting leukaemia stem cells: the path towards the cure of poor-prognosis leukaemia
34. CCIA - David Ziegler - Glioma
Radical new treatment for currently uncurable DIPG in Children
35. CCIA - Orazio Vittorio and Maria Kavallaris- All Tumours
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
36. Foundation for Surgery/Peter MacCallum – Toan Pham - Cancer Surgery
TetMYB vaccine has shown benefit in a prophylactic and therapeutic setting in the management of colonic adenoma in a murine model. This will form the basis for a future clinical trial to prevent and treat colonic adenomatous polyps.
37. Foundation for Surgery/ Peter MacCallum – Toan Pham - Cancer Surgery
Immunotherapy for Solid Tumors: A Review
38. CCIA – Paul Timpson, Phoebe Phillips - Pancreatic Cancer
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan
39. CCIA - Michelle Haber, Murray Norris, Glenn Marshall, David Ziegler - Neuroblastoma
Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma
40. Garvan – D. Neil Watkins - Lung Cancer
Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer
Together we are finding the answers. We won't fail. Thank you.
Find out how TDC is tackling cancer
"Funding from organisations like Tour de Cure is essential. It's particularly difficult to receive grants in the academic environment. Like many researchers and students, I'm very grateful for the tireless work it takes to raise such funds. Thank you!"
Dr Christopher Chan, Senior Scientist and TDC funding recipient
Help us to fund innovation and excellence
With your support, we can help bring new preventions and cures for cancer closer to reality. Please donate today.